Therapeutic Strategies of Denosumab Sequential Therapy: A Four-Armed Randomized Controlled Trial.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.70088
Abstract: After denosumab discontinuation, the rebound effect can lead to rapid bone loss and increased fracture risk. Identifying effective sequential therapies after denosumab discontinuation is crucial to mitigate these risks. We conducted the Denosumab Sequential Therapy… read more here.
Keywords: zoledronate; trial; group; zoledronate group ... See more keywords
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐Year Clinical Trial
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.3853
Abstract: Cessation of denosumab treatment is associated with increases in bone turnover above baseline values and rapid bone loss. We investigated the efficacy of zoledronate to prevent this bone loss in women with postmenopausal osteoporosis who… read more here.
Keywords: zoledronate; treatment; group; bone ... See more keywords
Zoledronate Reduces Height Loss Independently of Vertebral Fracture Occurrence in a Randomized Trial in Osteopenic Older Women
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4684
Abstract: Vertebral fractures are associated with height loss, reduced quality of life, and increased mortality and are an important endpoint for osteoporosis trials. However, height loss is associated with quality of life and mortality independent of… read more here.
Keywords: vertebral fracture; height loss; loss; trial ... See more keywords
Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate
Sign Up to like & getrecommendations! Published in 2017 at "Calcified Tissue International"
DOI: 10.1007/s00223-017-0257-4
Abstract: Bisphosphonates represent the gold-standard pharmaceutical agent for reducing fracture risk. Long-term treatment with bisphosphonates can result in tissue brittleness which in rare clinical cases manifests as atypical femoral fracture. Although this has led to an… read more here.
Keywords: significantly higher; zoledronate; treated zoledronate; treatment ... See more keywords
Bone Loss After Denosumab: Only Partial Protection with Zoledronate
Sign Up to like & getrecommendations! Published in 2017 at "Calcified Tissue International"
DOI: 10.1007/s00223-017-0288-x
Abstract: A case series of six women with postmenopausal osteoporosis who had received continuous denosumab for 7 years and were then given a single infusion of zoledronate (5 mg) is reported. During denosumab treatment, bone mineral density (BMD)… read more here.
Keywords: zoledronate; treatment; bmd; bone ... See more keywords
Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes
Sign Up to like & getrecommendations! Published in 2018 at "Drug Delivery and Translational Research"
DOI: 10.1007/s13346-018-0560-2
Abstract: In tumor microenvironment, tumor-associated macrophages (TAMs) are implicated in cancer sustainment, metastasis, and drug resistance, raising a growing interest as targets in cancer therapy. Since the bisphosphonate zoledronate has proven to affect TAMs’ functions, the… read more here.
Keywords: tumor; preclinical evaluation; zoledronate; evaluation innovative ... See more keywords
Effects of Treatment with a Bone-Targeted Prostaglandin E2 Receptor 4 Agonist C3 (Mes-1007) in a Mouse Model of Severe Osteogenesis Imperfecta.
Sign Up to like & getrecommendations! Published in 2021 at "Bone"
DOI: 10.1016/j.bone.2021.115867
Abstract: OBJECTIVE Osteogenesis imperfecta (OI) is a heritable bone fragility disorder that is usually caused by mutations affecting collagen type I synthesis in osteoblasts. Bisphosphonates are widely used to decrease fracture rate but are only partially… read more here.
Keywords: combination; zoledronate; treatment; mes 1007 ... See more keywords
Zoledronate prevents fractures in osteopenia
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Endocrinology"
DOI: 10.1038/s41574-018-0116-z
Abstract: Nature reviews | E n d o c r i n o l o g y Original article Reid, I. R. et al. Fracture prevention with zoledronate in older women with osteopenia. N. Engl. J.… read more here.
Keywords: fragility; zoledronate; preventing fractures; group ... See more keywords
Bone targeted new zoledronate derivative: design, synthesis, 99mTc-coupling, in-silico study and preclinical evaluation for promising osteosarcoma therapy
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Radiation Biology"
DOI: 10.1080/09553002.2022.2074162
Abstract: Abstract Background: Zoledronate suppresses human sarcomas by blocking the formation of geranylgeranyl diphosphate (GGPP) via inhibiting GGPP synthase. Objectives: Designing of new derivative of dronic acid (1-hydroxy-2-(4-nitro-1H-imidazol-1-yl)ethan-1,1-diyl)bis phosphonic acid), structurally related to zoledronate to be… read more here.
Keywords: osteosarcoma therapy; zoledronate; nitro zoledronate; bone targeted ... See more keywords
2306 Bone health after hip fracture; does introducing a 10-day vitamin D loading regime increase use of inpatient intravenous zoledro
Sign Up to like & getrecommendations! Published in 2024 at "Age and Ageing"
DOI: 10.1093/ageing/afae139.038
Abstract: Patients who experience a hip fracture have a high re-fracture risk. Prompt initiation of anti-osteoporosis treatment is therefore vital. Oral bisphosphonates are less well tolerated in some older people resulting in poor adherence. A single… read more here.
Keywords: hip fracture; vitamin loading; zoledronate; fracture ... See more keywords
Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate.
Sign Up to like & getrecommendations! Published in 2025 at "European journal of endocrinology"
DOI: 10.1093/ejendo/lvaf013
Abstract: OBJECTIVE Rebound vertebral fractures (VFs) after Denosumab (Dmab) withdrawal have been documented, highlighting the need for further research into this phenomenon and the importance of a well-planned strategy for discontinuing Dmab. METHODS From the TriNetX… read more here.
Keywords: zoledronate; fracture; withdrawal; risk ... See more keywords